Literature DB >> 21923730

Skin cancer screening in Germany - perception by the public.

Matthias Augustin1, Rudolf Stadler, Michael Reusch, Ines Schäfer, Thomas Kornek, Thomas Luger.   

Abstract

BACKGROUND: In 2008, community skin cancer screening (cSCS) was introduced into routine care of the German statutory health insurances (SHI). In the meantime, more than 13 million individuals have been screened. To date, no data are available on the perception of cSCS by the general public. AIM: Evaluation of public perception of cSCS in Germany. PATIENTS AND METHODS: From 10 to 17th March 2011, a phone survey on a population-based sample of n = 1 014 German adults with SHI status was conducted by the Forsa Institute, including 12 questions on the use, knowledge and attitude regarding cSCS.
RESULTS: Of the interviewees 48 % were concerned about skin cancer, 29 % of all persons and 31 % of those eligible had already undergone cSCS. Of these, a major proportion (80 %) had been screened by dermatologists. Of the interviewees 75 % would (again) consult a dermatologist for the next cSCS, and less than 10 % would consult the general practitioner. Although about 93 % considered health screenings useful, only 44 % were informed about the legal right to undergo free cSCS after the age of 35.
CONCLUSIONS: In Germany cSCS is highly accepted in the community. Leading care providers are the dermatologists. Knowledge about the right to free cSCS needs better public propagation.
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.

Entities:  

Mesh:

Year:  2011        PMID: 21923730     DOI: 10.1111/j.1610-0387.2011.07761.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  14 in total

1.  [Care for skin cancer in Germany : Provision and providers].

Authors:  M Augustin; Z Anastasiadou; M L Schaarschmidt; M Krensel; I Schäfer; M Reusch
Journal:  Hautarzt       Date:  2016-07       Impact factor: 0.751

2.  Public Perception of Management of Hair Conditions in America: Results from a National Survey.

Authors:  Alexandria Riopelle; Jacqueline Watchmaker; Lynne Goldberg
Journal:  Skin Appendage Disord       Date:  2020-04-15

3.  [Skin cancer screening in Germany : The situation in 2014 with suggestions for the future].

Authors:  A Blum; J Kreusch; W Stolz; H Haenssle
Journal:  Hautarzt       Date:  2015-07       Impact factor: 0.751

4.  [Perception of statutory skin cancer screening in the general population : Current findings on participation, knowledge and evaluation].

Authors:  L Eissing; I Schäfer; K Strömer; R Kaufmann; A Enk; M Reusch; M Augustin
Journal:  Hautarzt       Date:  2017-05       Impact factor: 0.751

5.  Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013.

Authors:  Alexander Katalinic; Nora Eisemann; Annika Waldmann
Journal:  Dtsch Arztebl Int       Date:  2015-09-18       Impact factor: 5.594

6.  [Primary prevention in the context of skin cancer screening].

Authors:  M Krensel; I Schäfer; N Zander; M Augustin
Journal:  Hautarzt       Date:  2019-06       Impact factor: 0.751

7.  [Regional differences in the health care of basal cell carcinoma].

Authors:  J Augustin; I Schäfer; P Thiess; M Reusch; M Augustin
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

8.  [Early detection of occupational skin diseases in sewer workers].

Authors:  V Lang; F Lauffer; Y Fincan; T Biedermann; A Zink
Journal:  Hautarzt       Date:  2018-09       Impact factor: 0.751

Review 9.  [Risk characteristics and survival rates of malignant melanoma in Germany and the Netherlands].

Authors:  J Augustin; I Schäfer; M Reusch; M Augustin
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

10.  Patient follow-up after participating in a beach-based skin cancer screening program.

Authors:  Mary L Greaney; Elaine Puleo; Alan C Geller; Stephanie W Hu; Andrew E Werchniak; Susan DeCristofaro; Karen M Emmons
Journal:  Int J Environ Res Public Health       Date:  2012-05-10       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.